Sera Prognostics inks deal with MultiPlan for pregnancy test

2022 02 01 23 05 7997 Business Contract Signing 400

Sera Prognostics has signed an agreement with MultiPlan to add its PreTRM pregnancy biomarker blood test to MultiPlan's private healthcare system (PHCS) and MultiPlan Networks.

As a result of the deal, more than 700 healthcare payers and 1.2 million healthcare providers participating in MultiPlan's provider networks will be able to order PreTRM Test, a proteomic blood test for measuring a woman's risk of spontaneous preterm birth.
Page 1 of 15
Next Page